Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0687-4
Abstract: Background and ObjectivesEvocalcet is a novel calcimimetic agent with potential to improve the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. This study aimed to determine the pharmacokinetics, pharmacodynamics, and safety of evocalcet… read more here.
Keywords: evocalcet healthy; evocalcet; safety; study ... See more keywords
P0886EFFICACY AND SAFETY OF EVOCALCET IN PERITONEAL DIALYSIS PATIENTS: A SINGLE CENTER LONGITUDINAL STUDY IN JAPAN
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0886
Abstract: Calcimimetic agent is used for secondaryhyperparathyroidism (SHPT), but it might cause gastrointestinal side-effects. These side effects are severe problem for PD patients with gastrointestinal symptoms due to dialysis fluid storage. Evocalcet is a new calcimimetic… read more here.
Keywords: evocalcet; level; occurred patients; safety evocalcet ... See more keywords